These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36504556)

  • 41. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
    Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
    Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
    Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
    [No Abstract]   [Full Text] [Related]  

  • 43. Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg.
    Katz PO; Le Moigne A; Pollack C
    Clin Ther; 2017 May; 39(5):960-970. PubMed ID: 28431766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis.
    Schneider H; Van Rensburg C; Schmidt S; Aboo N; Makela H; Nauclér E; Hallerback B; Svedberg LE
    Digestion; 2004; 70(4):250-6. PubMed ID: 15687727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
    Bayerdörffer E; Bigard MA; Weiss W; Mearin F; Rodrigo L; Dominguez Muñoz JE; Grundling H; Persson T; Svedberg LE; Keeling N; Eklund S
    BMC Gastroenterol; 2016 Apr; 16():48. PubMed ID: 27080034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis.
    Chen CY; Lu CL; Luo JC; Chang FY; Lee SD; Lai YL
    World J Gastroenterol; 2005 May; 11(20):3112-7. PubMed ID: 15918199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
    Moraes-Filho JP; Pedroso M; Quigley EM;
    Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.
    Iwakiri K; Sakurai Y; Shiino M; Okamoto H; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Ashida K
    Therap Adv Gastroenterol; 2017 Jun; 10(6):439-451. PubMed ID: 28567114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.
    Kahrilas PJ; Dent J; Lauritsen K; Malfertheiner P; Denison H; Franzén S; Hasselgren G
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1385-91. PubMed ID: 17950677
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection.
    Vakil NB; Traxler BM; Levine D
    Am J Gastroenterol; 2004 Aug; 99(8):1437-41. PubMed ID: 15307856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis.
    Maton PN; Vakil NB; Levine JG; Hwang C; Skammer W; Lundborg P;
    Drug Saf; 2001; 24(8):625-35. PubMed ID: 11480494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease.
    Kim DK; Lee KH; Kim SJ; Kim SJ; Lee SJ; Park CH; Kim BT; Song GS; Moon BS; Ryu SY
    J Pharmacol Exp Ther; 2019 Jun; 369(3):318-327. PubMed ID: 30894456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.
    Metz DC; Pilmer BL; Han C; Perez MC
    Am J Gastroenterol; 2011 Nov; 106(11):1953-60. PubMed ID: 21844923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.
    Tan VP; Wong WM; Cheung TK; Lai KC; Hung IF; Chan P; Pang R; Wong BC
    J Gastroenterol; 2011 Jul; 46(7):906-12. PubMed ID: 21538030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study.
    Atug O; Giral A; Kalayci C; Dolar E; Isitan F; Oguz D; Ovunc O; Ozgur O; Soykan I; Simsek I; Unal S; Yenice N;
    Adv Ther; 2008 Jun; 25(6):552-66. PubMed ID: 18568450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial.
    Sun QH; Wang HY; Sun SD; Zhang X; Zhang H
    World J Gastroenterol; 2019 May; 25(17):2110-2121. PubMed ID: 31114137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
    Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP; Wu TS; Dan YY
    J Clin Pharm Ther; 2015 Aug; 40(4):368-75. PubMed ID: 25893507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
    Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
    Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.